Hyperimmunoglobulin D syndrome
A periodic fever syndrome with elevated immunoglobulin D.
Hyperimmunoglobulin D syndrome (HIDS) is a mild manifestation of mevalonate kinase deficiency (MKD), an autosomal recessive metabolic disorder that disrupts the biosynthesis of cholesterol and isoprenoids. It is a periodic fever syndrome originally described in 1984 by the internist Jos van der Meer, then at Leiden University Medical Centre. HIDS is characterized by attacks of fever, arthralgia, skin lesions including cyclical mouth ulcers, and diarrhea, with laboratory features including an acute phase response and markedly elevated IgD (and often IgA).
- Field
- Medicine, Genetics
- Known for
- Mild form of mevalonate kinase deficiency, periodic fever syndrome with elevated IgD
- First described
- 1984
- Inheritance
- Autosomal recessive
- Gene locus
- 12q14
- Prevalence
- Less than 1 in 100,000 people globally
Lore & Background
Hyperimmunoglobulin D syndrome was first described in 1984 by internist Jos van der Meer at Leiden University Medical Centre. It is now recognized as a mild manifestation of mevalonate kinase deficiency, caused by pathogenic variants in the gene encoding mevalonate kinase. The most common variants are V377I, I268T, H20P/N and P167L, present in 70% of affected individuals. The disorder has mainly been described in the Netherlands and France, although the international registry includes cases from other countries.
Reader's Guide
Hyperimmunoglobulin D syndrome represents a milder, more common form of mevalonate kinase deficiency, a rare autosomal recessive metabolic disorder. Its significance lies in its classification as a periodic fever syndrome, first identified in 1984, and its link to the mevalonate pathway, which is crucial for cholesterol and isoprenoid biosynthesis. The disorder highlights the role of defective protein prenylation in driving inflammation through activation of the pyrin and NLRP3 inflammasome. Treatment options include IL-1 targeting drugs such as anakinra and canakinumab, with canakinumab approved for HIDS. Anti-TNF therapy may be partially effective, and statin drugs are under investigation. The condition is rare, with less than 1 in 100,000 people affected globally, and about 200 individuals having MKD overall. Understanding HIDS has contributed to broader knowledge of autoinflammatory diseases and the mevalonate pathway's role in immune regulation.
A Rare Autoinflammatory Condition
Hyperimmunoglobulin D syndrome occupies a distinctive niche among rare medical conditions. Rather than being an autoimmune disease in the traditional sense, HIDS is classified as an autoinflammatory disorder — a category in which the body's innate immune system fires off inflammatory responses without any external pathogen or autoantibody driving the process. The name itself encodes one of its hallmark laboratory findings: persistently elevated levels of immunoglobulin D in the blood, often accompanied by raised immunoglobulin A. The condition is exceedingly uncommon, affecting children and adults across populations worldwide, and its rarity has historically made diagnosis a challenge, with many patients spending years receiving incorrect explanations for their recurring symptoms. Because the inflammatory episodes are self-limiting yet relentless in their recurrence, HIDS sits at an uncomfortable intersection between benign and debilitating in the eyes of both patients and clinicians.
The Genetic Underpinning
At its molecular core, HIDS is a disorder of the mevalonate pathway, a critical biochemical route involved in cholesterol and isoprenoid synthesis. The condition arises from mutations in the MVK gene, which encodes the enzyme mevalonate kinase. Inheritance follows an autosomal recessive pattern, meaning an individual must carry two defective copies of the gene — one from each parent — to manifest the syndrome. Heterozygous carriers typically remain asymptomatic, though they may show subtle laboratory abnormalities. The severity of clinical expression can vary considerably even among affected individuals, a phenomenon attributed to the specific nature of the mutation and its effect on residual enzyme activity. This genetic architecture places HIDS firmly within the family of congenital and hereditary disorders, linking it to the broader catalog of conditions passed through familial lines rather than acquired through environmental exposure.
The Recurrent Episode
The clinical signature of HIDS is a pattern of recurrent, self-resolving inflammatory episodes that can begin in infancy or early childhood and persist throughout life. A typical flare is heralded by a sudden spike in fever, often reaching high temperatures, accompanied by a constellation of symptoms that may include joint pain and swelling, a characteristic skin rash, abdominal discomfort, and in some cases, swollen lymph nodes. Episodes generally last between two and seven days before resolving spontaneously, leaving the patient in a symptom-free interval that can range from weeks to months. The unpredictability of timing is one of the most psychologically taxing aspects of living with the condition, as patients can never be entirely certain when the next wave of inflammation will strike. The episodic nature distinguishes HIDS from chronic progressive diseases, yet the cumulative burden of repeated flares can significantly impair quality of life and daily functioning.
Place in the Broader Medical Landscape
Within the taxonomy of medical syndromes, HIDS finds its natural home alongside other congenital and genetic disorders — conditions rooted in inherited biological variation rather than acquired injury or infection. It is frequently discussed in the same breath as other autoinflammatory syndromes, forming a recognized family of diseases in which dysregulated innate immunity produces periodic inflammatory storms. The condition's inclusion in alphabetical catalogs of medical syndromes, positioned under the letter H, reflects its status as a distinct, named entity in medical literature. Clinically, HIDS shares management strategies with its autoinflammatory relatives, including the use of anti-inflammatory agents and, in more refractory cases, targeted biologic therapies that interrupt specific cytokine pathways. Its recognition as a separate entity from the more severe mevalonate kinase deficiency spectrum underscores the importance of precise genetic and phenotypic characterization in modern medicine.
More in Autoinflammatory syndromes 1-24
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced